These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 21838595)

  • 61. Comment on the potential utility of the new atypical antipsychotic lurasidone in the geriatric population.
    Guay DR
    Consult Pharm; 2011 Aug; 26(8):579-82. PubMed ID: 21840821
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Acute lurasidone overdose.
    Molnar GP; Grimsich LC; Catalano G; Catalano MC
    J Clin Psychopharmacol; 2014 Dec; 34(6):768-70. PubMed ID: 25285434
    [No Abstract]   [Full Text] [Related]  

  • 63. Oral bioavailability and pharmacokinetics of PAT-5A, a new insulin sensitizer in rats.
    Mamidi RN; Katneni K; Mullangi R; Ramanujam R
    Eur J Drug Metab Pharmacokinet; 2002; 27(3):175-8. PubMed ID: 12365198
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacokinetic Characterization of Supinoxin and Its Physiologically Based Pharmacokinetic Modeling in Rats.
    Song YK; Seol YH; Kim MJ; Jeong JW; Choi HI; Lee SW; Chae YJ; Ahn S; Gong YD; Lee KR; Koo TS
    Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33799884
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pharmacokinetics and tissue distribution of olanzapine in rats.
    Aravagiri M; Teper Y; Marder SR
    Biopharm Drug Dispos; 1999 Nov; 20(8):369-77. PubMed ID: 10870093
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effect of carbamazepine on the single oral dose pharmacokinetics of perospirone and its active metabolite.
    Masui T; Kusumi I; Takahashi Y; Koyama T
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1330-3. PubMed ID: 16600452
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Evaluation of Marine Diindolinonepyrane in Vitro and in Vivo: Permeability Characterization in Caco-2 Cells Monolayer and Pharmacokinetic Properties in Beagle Dogs.
    Ma Z; Guo R; Elango J; Bao B; Wu W
    Mar Drugs; 2019 Nov; 17(12):. PubMed ID: 31757085
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Single Dose Oral and Intravenous Pharmacokinetics and Tissue Distribution of a Novel Hesperetin Derivative MTBH in Rats.
    Shen C; Qian Z; Chen R; Meng X; Hu T; Chen Z; Li Y; Huang C; Hu C; Li J
    Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):675-688. PubMed ID: 26254910
    [TBL] [Abstract][Full Text] [Related]  

  • 69. ACS chemical neuroscience molecule spotlight on latuda (lurasidone; SM-13,496).
    Hopkins CR
    ACS Chem Neurosci; 2011 Feb; 2(2):58-9. PubMed ID: 22778856
    [No Abstract]   [Full Text] [Related]  

  • 70. Antipsychotic lurasidone: Behavioural and pharmacokinetic data in C57BL/6 mice.
    Percelay S; Since M; Lagadu S; Freret T; Bouet V; Boulouard M
    Pharmacol Biochem Behav; 2020 Jul; 194():172933. PubMed ID: 32371059
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Structural insight into receptor-selectivity for lurasidone.
    Ichikawa O; Okazaki K; Nakahira H; Maruyama M; Nagata R; Tokuda K; Horisawa T; Yamazaki K
    Neurochem Int; 2012 Dec; 61(7):1133-43. PubMed ID: 22929996
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pre-clinical investigation of the modulation of quetiapine plasma pharmacokinetics and tissues biodistribution by lipid-core nanocapsules.
    Carreño F; Paese K; Silva CM; Guterres SS; Dalla Costa T
    J Pharm Biomed Anal; 2016 Feb; 119():152-8. PubMed ID: 26683988
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Distribution of perospirone to melanin in pigmented rats.
    Mizuno Y; Komuro S; Kanamaru H
    Eur J Drug Metab Pharmacokinet; 2003; 28(1):73-9. PubMed ID: 14503668
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Physiologically based pharmacokinetic modeling of SNU-0039, an anti-Alzheimer's agent, in rats.
    Lee KR; Chae YJ; Maeng HJ; Lee J; Kim DD; Chong S; Shim CK; Chung SJ
    J Pharmacokinet Pharmacodyn; 2011 Oct; 38(5):637-51. PubMed ID: 21866408
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinically important differences in the pharmacokinetics of the ten newer "atypical" antipsychotics: Part 3. Effects of renal and hepatic impairment.
    Preskorn SH
    J Psychiatr Pract; 2012 Nov; 18(6):430-7. PubMed ID: 23160248
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Specific features in pharmacokinetics of the original neuroleptic dilept in animals and humans].
    Shevchenko RV; Litvin AA; Kolyvanov GB; Boĭko SS; Zherdev VP
    Eksp Klin Farmakol; 2014; 77(7):23-6. PubMed ID: 25322650
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Distribution of the methylpiperazinopyridobenzoxazepine derivative JL13, a potential antipsychotic, in rat brain.
    Guiso G; Caccia S
    J Pharm Pharmacol; 2001 Mar; 53(3):317-21. PubMed ID: 11291746
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Estimation of tritiated water formation following multiple oral doses of a tritium-labeled compound.
    Wang Y; Tse FL
    J Pharm Sci; 1998 Jan; 87(1):123-4. PubMed ID: 9452980
    [No Abstract]   [Full Text] [Related]  

  • 79. Prominently selective fluorescence approach with distinctive biopharmaceutical utility for analysis of lurasidone in human plasma and urine: Application to in vitro dissolution and content uniformity testing.
    Mostafa YE; Metwally ME; Elsebaei F
    Luminescence; 2024 Sep; 39(9):e4887. PubMed ID: 39238324
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Factors associated with increased risk of lurasidone-induced somnolence: Two case-control studies based on one bioequivalence trial in healthy volunteers.
    Yu H; Qi X; Fang Y; Wang K; Zhang D; Chen Q; Liu D; Ren X
    Heliyon; 2023 Jul; 9(7):e17905. PubMed ID: 37539152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.